Check-Cap Stock (NASDAQ:CHEK)


ForecastOwnershipChart

Previous Close

$0.69

52W Range

$0.56 - $3.04

50D Avg

$0.80

200D Avg

$1.28

Market Cap

$3.94M

Avg Vol (3M)

$170.55K

Beta

-0.26

Div Yield

-

CHEK Company Profile


Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

85

IPO Date

Mar 04, 2015

Website

CHEK Performance


Peer Comparison


TickerCompany
NOTVInotiv, Inc.
STIMNeuronetics, Inc.
BNRBurning Rock Biotech Limited
PREPrenetics Global Limited
ACRSAclaris Therapeutics, Inc.
DRIODarioHealth Corp.
CSTLCastle Biosciences, Inc.
BDSXBiodesix, Inc.
SERASera Prognostics, Inc.
FONRFONAR Corporation
MDXHMDxHealth SA